ArticleNeuro-oncology advances
Risk factors, predictive models, and general work ability trajectory in patients with glioma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma research has increasingly emphasized quality of life alongside traditional survival metrics, emphasizing functional outcomes, symptom burden, and social reintegration, including the ability to work. While previous studies focused on return-to-work rates, we assessed general work ability as a broader measure of work capacity. We aimed to develop predictive models for general work ability recovery, identify key risk factors, and explore long-term trajectories. Methods: We conducted a retrospective cohort study of 342 patients with glioma (aged 18-64, WHO Grades 2-4) between March 2010 and December 2018. Work ability and symptoms were assessed using the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT), which was administered at months 1 and 3 postoperatively, then every three months up to 12 months, and at longer intervals thereafter. Logistic regression predicted 6-month general work ability recovery, and Cox models identified long-term risk factors. Long-term monitoring was conducted to evaluate the stability of work ability recovery across different WHO grades. Results: 65.2% (223/342) regaining general work ability within 6 months post-surgery. Brain tumor-specific symptoms were stronger predictors of recovery than general symptoms. Predictive models achieved AUCs of 0.78 (pre-surgery) and 0.82 (post-surgery). Long-term monitoring showed recovery instability, with cumulative recovery rates for WHO Grades 2-4 at 82.1%, 50.8%, and 28.2%, respectively, while peaks at 50.8%, 28.3%, and 7.3%. Conclusions: Brain tumor-specific symptoms significantly impact general work ability recovery. Recovery instability was observed across all patients, underscoring the importance of targeted symptom management, personalized care, and sustained follow-up to improve quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.